Evidence Based Medicine on FHIR Implementation Guide
2.0.0-ballot - ballot
Evidence Based Medicine on FHIR Implementation Guide
2.0.0-ballot - ballot
Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 2.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions
{
"resourceType" : "Group",
"id" : "179619",
"meta" : {
"versionId" : "4",
"lastUpdated" : "2023-12-06T00:11:33.141Z",
"profile" : [
🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/systematic-review-eligibility-criteria"
]
},
"text" : {
"status" : "extensions",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p class=\"res-header-id\"><b>Generated Narrative: Group 179619</b></p><a name=\"179619\"> </a><a name=\"hc179619\"> </a><a name=\"179619-en-US\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">version: 4; Last updated: 2023-12-06 00:11:33+0000</p><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-systematic-review-eligibility-criteria.html\">SystematicReviewEligibilityCriteria</a></p></div><p><b>Artifact related artifact</b>: No display for RelatedArtifact (type: cite-as; citation: SystematicReviewEligibilityCriteria: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer [Group]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 179619. Revised 2023-12-04. Available at: https://fevir.net/resources/Group/179619. Computable resource at: https://fevir.net/resources/Group/179619.)</p><p><b>Artifact Author</b>: Brian S. Alper: </p><p><b>url</b>: <a href=\"https://fevir.net/resources/Group/179619\">https://fevir.net/resources/Group/179619</a></p><p><b>identifier</b>: FEvIR Object Identifier/179619</p><p><b>name</b>: SystematicReviewEligibilityCriteria_ADT_and_Docetaxel_vs_ADT_alone_for_metastatic_hormone_naive_prostate_cancer</p><p><b>title</b>: SystematicReviewEligibilityCriteria: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer</p><p><b>status</b>: Active</p><p><b>publisher</b>: Computable Publishing LLC</p><p><b>contact</b>: <a href=\"mailto:support@computablepublishing.com\">support@computablepublishing.com</a></p><p><b>description</b>: </p><div><p><strong>Study selection criteria</strong>\nTypes of Studies.\nRandomized controlled clinical trials (RCTs) with parallel design that compared the association of ADT and chemotherapy (docetaxel), versus ADT alone.</p>\n<p>Types of participants.\nPatients aged ≥18 years with cytological or histological diagnosis of mHNPC.</p>\n</div><h3>UseContexts</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Code</b></td><td><b>Value[x]</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"CodeSystem-179423.html#179423-evidence-communication\">Evidence Based Medicine on FHIR Implementation Guide Code System evidence-communication</a>: Evidence Communication</td><td><span title=\"Codes:{https://fevir.net/resources/CodeSystem/179423 SystematicReviewEligibilityCriteria}\">SystematicReviewEligibilityCriteria</span></td></tr></table><p><b>copyright</b>: </p><div><p>https://creativecommons.org/licenses/by-nc-sa/4.0/</p>\n</div><p><b>membership</b>: Conceptual</p><p><b>combinationMethod</b>: All of</p><blockquote><p><b>characteristic</b></p><p><b>code</b>: <span title=\"Codes:\">Study Design</span></p><p><b>value</b>: <span title=\"Codes:{https://fevir.net/resources/CodeSystem/181513 SEVCO:01003}\">randomized assignment</span></p><p><b>exclude</b>: false</p><p><b>description</b>: </p><div><p>Randomized controlled clinical trials (RCTs)</p>\n</div></blockquote><blockquote><p><b>characteristic</b></p><p><b>code</b>: <span title=\"Codes:\">Study Design</span></p><p><b>value</b>: <span title=\"Codes:{https://fevir.net/resources/CodeSystem/181513 SEVCO:01011}\">Parallel cohort design</span></p><p><b>exclude</b>: false</p><p><b>description</b>: </p><div><p>parallel design</p>\n</div></blockquote><blockquote><p><b>characteristic</b></p><p><b>code</b>: <span title=\"Codes:\">Comparison</span></p><p><b>value</b>: GroupAssignment: ADT plus docetaxel vs. ADT alone</p><p><b>exclude</b>: false</p><p><b>description</b>: </p><div><p>compared the association of ADT and chemotherapy (docetaxel), versus ADT alone</p>\n</div></blockquote><blockquote><p><b>characteristic</b></p><p><b>code</b>: <span title=\"Codes:{http://snomed.info/sct 397669002}\">Age</span></p><p><b>value</b>: >=18 years<span style=\"background: LightGoldenRodYellow\"> (Details: UCUM codea = 'a')</span></p><p><b>exclude</b>: false</p><p><b>description</b>: </p><div><p>Types of participants.\nPatients aged ≥18 years</p>\n</div><p><b>method</b>: <span title=\"Codes:\">applied to participants in the studies</span></p></blockquote><blockquote><p><b>characteristic</b></p><p><b>code</b>: <span title=\"Codes:{http://snomed.info/sct 64572001}\">Disease (disorder)</span></p><p><b>value</b>: <span title=\"Codes:\">metastatic hormone-naive prostate cancer</span></p><p><b>exclude</b>: false</p><p><b>description</b>: </p><div><p>Types of participants.\nPatients with cytological or histological diagnosis of mHNPC.</p>\n</div><p><b>method</b>: <span title=\"Codes:\">applied to participants in the studies</span>, <span title=\"Codes:\">cytological or histological diagnosis</span></p></blockquote></div>"
},
"extension" : [
{
"url" : "http://hl7.org/fhir/StructureDefinition/artifact-relatedArtifact",
"valueRelatedArtifact" : {
"type" : "cite-as",
"citation" : "SystematicReviewEligibilityCriteria: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer [Group]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 179619. Revised 2023-12-04. Available at: https://fevir.net/resources/Group/179619. Computable resource at: https://fevir.net/resources/Group/179619."
}
},
{
"url" : "http://hl7.org/fhir/StructureDefinition/artifact-author",
"valueContactDetail" : {
"name" : "Brian S. Alper"
}
}
],
"url" : "https://fevir.net/resources/Group/179619",
"identifier" : [
{
"type" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/v2-0203",
"code" : "ACSN",
"display" : "Accession ID"
}
],
"text" : "FEvIR Object Identifier"
},
"system" : "https://fevir.net",
"value" : "179619",
"assigner" : {
"display" : "Computable Publishing LLC"
}
}
],
"name" : "SystematicReviewEligibilityCriteria_ADT_and_Docetaxel_vs_ADT_alone_for_metastatic_hormone_naive_prostate_cancer",
"title" : "SystematicReviewEligibilityCriteria: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer",
"status" : "active",
"publisher" : "Computable Publishing LLC",
"contact" : [
{
"telecom" : [
{
"system" : "email",
"value" : "support@computablepublishing.com"
}
]
}
],
"description" : "**Study selection criteria**\nTypes of Studies.\nRandomized controlled clinical trials (RCTs) with parallel design that compared the association of ADT and chemotherapy (docetaxel), versus ADT alone.\n\nTypes of participants.\nPatients aged ≥18 years with cytological or histological diagnosis of mHNPC.",
"useContext" : [
{
"code" : {
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "evidence-communication",
"display" : "Evidence Communication"
},
"valueCodeableConcept" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "SystematicReviewEligibilityCriteria",
"display" : "SystematicReviewEligibilityCriteria"
}
]
}
}
],
"copyright" : "https://creativecommons.org/licenses/by-nc-sa/4.0/",
"membership" : "conceptual",
"combinationMethod" : "all-of",
"characteristic" : [
{
"code" : {
"text" : "Study Design"
},
"valueCodeableConcept" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/181513",
"code" : "SEVCO:01003",
"display" : "randomized assignment"
}
]
},
"exclude" : false,
"description" : "Randomized controlled clinical trials (RCTs)"
},
{
"code" : {
"text" : "Study Design"
},
"valueCodeableConcept" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/181513",
"code" : "SEVCO:01011",
"display" : "Parallel cohort design"
}
]
},
"exclude" : false,
"description" : "parallel design"
},
{
"code" : {
"text" : "Comparison"
},
"valueReference" : {
"type" : "EvidenceVariable",
"display" : "GroupAssignment: ADT plus docetaxel vs. ADT alone"
},
"exclude" : false,
"description" : "compared the association of ADT and chemotherapy (docetaxel), versus ADT alone"
},
{
"code" : {
"coding" : [
{
"system" : "http://snomed.info/sct",
"code" : "397669002",
"display" : "Age"
}
]
},
"valueQuantity" : {
"value" : 18,
"comparator" : ">=",
"unit" : "years",
"system" : "http://unitsofmeasure.org",
"code" : "a"
},
"exclude" : false,
"description" : "Types of participants.\nPatients aged ≥18 years",
"method" : [
{
"text" : "applied to participants in the studies"
}
]
},
{
"code" : {
"coding" : [
{
"system" : "http://snomed.info/sct",
"code" : "64572001",
"display" : "Disease (disorder)"
}
]
},
"valueCodeableConcept" : {
"text" : "metastatic hormone-naive prostate cancer"
},
"exclude" : false,
"description" : "Types of participants.\nPatients with cytological or histological diagnosis of mHNPC.",
"method" : [
{
"text" : "applied to participants in the studies"
},
{
"text" : "cytological or histological diagnosis"
}
]
}
]
}
IG © 2024+ HL7 International / Clinical Decision Support. Package hl7.fhir.uv.ebm#2.0.0-ballot based on FHIR 6.0.0-ballot2. Generated 2024-12-19
Links: Table of Contents |
QA Report
| Version History |
|
Propose a change